[EN] HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS [FR] ACIDES HÉTÉROARYL-CARBOXYLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
[EN] 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS [FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6
[EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010036632A1
公开(公告)日:2010-04-01
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
申请人:BOEHRINGER INGELHEIM INTERNATIONAL GMBH
公开号:EP2346868A1
公开(公告)日:2011-07-27
1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS
申请人:Oryzon Genomics, S.A.
公开号:US20200339569A1
公开(公告)日:2020-10-29
The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.
[EN] 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS<br/>[FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6
申请人:ORYZON GENOMICS SA
公开号:WO2019110663A1
公开(公告)日:2019-06-13
The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.
[EN] HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS<br/>[FR] ACIDES HÉTÉROARYL-CARBOXYLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
申请人:ORYZON GENOMICS SA
公开号:WO2017207813A1
公开(公告)日:2017-12-07
The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.